New Quinoline Kinase Inhibitors With Good Selectivity for NAK Kinases and Anti-Tumor Activity Against Ewing Sarcoma

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Limited therapeutic advancements for childhood cancers, particularly Ewing Sarcoma (ES).
• Protein kinase inhibitors represent a growing class of anticancer agents, but few target pediatric malignancies.
• Ewing Sarcoma is a common and aggressive bone cancer in children.

Purpose of the Study:

• To identify novel therapeutic agents for Ewing Sarcoma (ES).
• To investigate the anti-proliferative activity of novel 4,6-disubstituted quinoline derivatives against ES.
• To determine the kinase selectivity profile of promising quinoline derivatives.

Main Methods:

• Screening of an in-house quinoline chemical library.
• Evaluation of anti-proliferative activity against Ewing Sarcoma cell lines.
• Kinase inhibition assays and enzyme kinetics to determine selectivity and potency.

Main Results:

• Identification of 4,6-disubstituted quinoline derivatives with significant anti-proliferative effects on ES.
• Demonstrated generally narrow kinase selectivity profiles for the identified compounds.
• Specific inhibition of NAK family kinases, notably cyclin G-associated kinase (GAK), in the nanomolar range.

Conclusions:

• Novel quinoline derivatives exhibit potent anti-proliferative activity against Ewing Sarcoma.
• Targeting cyclin G-associated kinase (GAK) with these quinoline derivatives presents a potential therapeutic strategy for pediatric ES.
• Further investigation into these compounds could expand treatment options for childhood bone cancers.